Considerations on the mechanisms involved on the benefits of GM1 treatment of mice with experimental Chagas´ disease
Abstract
Background: In previous papers, some of us reported that GM1 improve the condition of with acute Trypanosoma cruzi infection but the mechanisms proposed did not involve adrenergic or steroid receptors.
Methods: 160 three months old outbreed Albino Swiss mice were divided in four groups: a) non-infected, b) non-infected and treated with GM1 0,1 mg /day by intramuscular injection, for 30 days, c) infected with T. cruzi, 0.7´105 parasites, d) infected with T. cruzi, 0.7´105 parasites and treated with GM1 0,1 mg /day by intramuscular injection for 30 days. The animals were studied at 35 days from the beginning of treatment and at 120 days post treatment. Cardiomyocyte membranes were isolated and β adrenergic receptors, membrane fluidity and composition, plasma glucose, potassium, DHA, estradiol and cortisol were determined. Histological sections of heart and adrenal glands were examined.
Results: At day 35 receptor Kd (nM) was 3.6; 4.46; 1.89 for healthy, infected, and infected GM1 treated mice and Bmax (fmol/mg prot) was 71.9; 54.8 and 21.14 respectively. At 120 days Kd for each group was 4.6; 4.6; and 2.79 respectively and Bmax was 71.9; 54.89; 74.2 respectively. Fluorescence anisotropy was reduced by infection and GM1 treatment from 0.88; 0.56; 0.43 for healthy, infected, and infected GM1 treated mice.
GM1 treatment increased plasma estradiol in both sexes uninfected mice. Chronically infected mice with prolonged QT 59.5 ms presented 48.9 ms after GM1. Histology of cardiac muscle slices showed no fibrosis and adrenal glands remodeling.
Conclusions: GM1 improved the condition of acute lethal infected and chronically infected mice regulating beta adrenergic receptors directly or through the modulation of steroids hormones. The observed evolution was concomitant with structural tissue modifications.
Keywords
Full Text:
PDFReferences
Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M. Chagas' disease. Clin Microbiol Rev. 1992 Oct;5(4):400-19.
Jörg M, Storino R Consenso de la Enfermedad de Chagas. La enfermedad de Chagas en el siglo XXI. Consenso para una asignatura pendiente. Rev. Argent. Cardiol. 70 (Supl 1) 910
Mordini O.D.; Bavio E.; Beloscar J. ; Tognoni G. ; Sosa F.J.; Reyes O.; Pairone E.; Lacunza D.; Manzur R.; Redondo M.; Hernández D.; Mujica H., Olavegogeoescoechea P.. Chagas Disease in Argentina. "National Registry of Chagas Disease of the ‘Federación Argentina de Cardiología’. RENECH study. Revista FAC, 2016, Sumario Vol. 45 (No 2) Abril-Junio.
Altcheh J., Moscatelli G., Moroni S., Garcia-Bournissen F., Freilij H. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011, 127: 212-218.
Altcheh J., Moscatelli G., Mastrantonio G., Moroni S., Giglio N., et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014, 8: e2907. doi: 10.1371/journal.pntd.0002907 PMID: 24853169
Sartor P., Colaianni I., Cardinal M.V., Bua J., Freilij H., Gürtler R.E.) Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation. PLoS Negl Trop Dis, 2017, 11(2): e0005336. doi:10.1371/journal.
Luján H.D., Paglini P., Fretes R., Fernández A., Fidelio G.D., Bronia DH. Effect of gangliosides on Trypanosoma cruzi infection in mice. Life Sci. 1993;53(5):PL69-73.
Bronia D.H., Pereira B.M., Luján H.D., Fretes R.E., Fernández A., Paglini P.A.. Ganglioside treatment of acute Trypanosoma cruzi infection in mice promotes long-term survival and parasitological cure. Ann Trop Med Parasitol. 1999, 93(4):341-50.
Cossy Isasi S., Fernandez A.R., Paglini P., Bronia D.H.. GM1 ganglioside induced myocardial restoration and survival of mice with experimental Chagas' disease. Acta Trop. 1999; 73(3):295-302.
Sterin-borda l, Perez Leiros C, Wald M, Cremaschi G, Borda E. Antibodies to beta 1 and beta 2 adrenoreceptors in Chagas' disease. Clin Exp Immunol;1988; 74 (3):349-54.
Rosenbaum M.B., Chiale P.A., Schejtman D., Levin M., Elizari M.V.. Antibodies to beta-adrenergic receptors disclosing agonist-like properties in idiopathic dilated cardiomyopathy and Chagas' heart disease. J Cardiovasc Electrophysiol., 1994; 5(4):367-75.
Paglini-Oliva P, Fernandez-Culasso A, Lacuara JL., Pharmacological and contractile response of myocardium of Chagasic albino Swiss mice. Acta Physiol Pharmacol Latinoam; 37 (3):395-401
Enders JE, Paglini P, Fernandez AR, Marco F, Palma JA.., Cardiac beta-receptors in experimental Chagas' disease. Rev Inst Med Trop Sao Paulo, 1995; 37(1):59-62
Lo Presti M.S., Bustamante J.M., Rivarola W.H., Fernández A.R., Enders J.E., Fretes R., Levin G., PaglinI-Oliva P.A.. Changes in the cardiac beta-adrenergic system provoked by different T. cruzi strains. Int J Cardiol. 2006; 111(1):104-12. Epub 2005 Oct 24.
Fernandez AR, Enders JE, Rivarola W, Paglini P, Palma JA.. Cardiac beta receptors' density or affinity modified by different Trypanosoma cruzi amount. Acta Physiol Pharmacol Ther Latinoam, 1996; 46(2):139-43
Herda L.R., Felix S.B. and Boege F. Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on humanheart function. British Journal of Pharmacology (2012) 166 847–857.
Patel P. A. and Hernandez A. F.. Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. European Journal of Heart Failure (2013) 15, 724–729.
Bornholz B., Roggenbuck D., Jahns R., Boege F.. Diagnostic and therapeutic aspects of β1-adrenergic receptor autoantibodies in human heart disease. Autoimmunity Reviews 13 (2014) 954–962.
Becker N.P., Müller J., Göttel P., Wallukat G., Schimke I.. Cardiomyopathy — An approach to the autoimmune background. Autoimmunity Reviews 16 (2017) 269–286.
CremaschI G, Zwirner NW, Gorelik G, Malchiodi EL, Chiaramonte MG, Fossati CA, Sterin-Borda L., Modulation of cardiac physiology by an anti-Trypanosoma cruzi monoclonal antibody after interaction with myocardium. FASEB J.. 1995; 9(14):1482-8.
Borda ES, Sterin-Borda L. Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy. Int J Cardiol., 1996; 54(2):149-56
Goin JC, Venera G, Biscoglio de Jimenez Bonino M, Sterin-Borda L. Circulating antibodies against nicotinic acetylcholine receptors in chagasic patients. Clin Exp Immunol., 1997; 110(2):219-25
Goin JC, Borda ES, Auger S, Storino R, Sterin-Borda L., Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia, Heart, 1999 ; 82(3):273-8
Vidal Jiménez M.A., Nascimento J.H.M., Monnerat G., Maciel L., Paiva C.N.,Coury Pedrosa R., Campos de Carvalho A.C., Medei E.. Autoantibodies with beta-adrenergic activity from chronic chagasic patients induce cardiac arrhythmias and early afterdepolarization in a drug-induced LQT2 rabbit hearts Int J Cardiol. , Mar 2017 1. pii: S0167-5273(16)33458-1
Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy,. Herz, 2000; 25 (3):261-6
Goin JC, Borda E, Segovia A, Sterin-Borda L., Distribution of antibodies against beta-adrenoceptors in the course of human Trypanosoma cruzi infection. Proc Soc Exp Biol Med., 1991; 197(2):186-92.
Lakowicz, JR (1984). Principles of Fluorescence Spectroscopy, Chap. 5, Plenum, NewYork
Cossy Isasi S, Condat CA, Sibona GJ. Why does GM1 induce a potent beneficial response to experimental Chagas disease? HFSP J. 2009;3(2):142-51.
Fan S., Wang S., Kao Y.. Enhancement of β-Adrenergic Receptor Activation of Maxi-K+ Channels by GM1 Ganglioside. BBRC, 1994,Vol 2000 (No 3), 1341-1345.
Saito M, Frielle T, Benovic JL, Ledeen RW., Modulation by GM1 ganglioside of β1-adrenergic receptor-induced cyclic AMP formation in Sf9 cells. Biochim Biophys Acta., 1995; 1267 (1):1-5.
Prasanna X., Jafurulla M., Sengupta D., Chattopadhyay A.. The ganglioside GM1 interacts with the serotonin1A receptor via the sphingolipid binding domain. Biochim Biophys Acta. 2016 Nov;1858(11):2818-2826
Ma Z., Lee S.S. and Meddings J.B. Effects of altered cardiac membrane fluidity on adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. Journal of Hepatology 1997; 26:904-912.
Allen J.A., Halverson-Tamboli R.A. and Rasenick M.M. Lipid raft microdomains and neurotransmitter signalling. Nature Reviews Neuroscience, Vol 8, 2007, 128-140
Bechler M. E., De Figueiredo P. and Brown, W. J. A PLA1-2 punch regulates the Golgi complex. Trends Cell Biol., 2012; 22, 116-124.
Andreis P.G., Buttazzi P, Tortorella C, De Carol R., Aragona F., Neri G and Nussdorfer G.G. The inhibitor of phospholipase-A2, AACOCF3,stimulates steroid secretion by dispersed human and rat adrenocortical cells. Life Sci., 1999; Vol. 64(No. 15), pp. 1287- 1294.
Wu Q, Zhao Z, Sun H, Hao YL, Yan CD, Gu SL. Oestrogen changed cardiomyocyte contraction and β-adrenoceptor expression in rat hearts subjected to ischaemia–reperfusion. Exp Physiol 93.(9) pp 1034–1043.
Rodriguez-Hernandez A, Rubio-Gayosso I, Ramirez I, Ita-Islas I, Meaney E, GAXIOLA S, Meaney A, Asbun J, Figueroa-Valverde L, Ceballos G. Intraluminal-restricted 17 beta-estradiol exerts the same myocardial protection against ischemia/reperfusion injury in vivo as free 17 beta-estradiol. Steroids. 2008; 73(5):528-38.
Lourenço AM1, Levy AM, Caetano LC, Carraro Abrahão AA, Prado JC Jr. Influence sexual dimorphism on the persistence of blood parasites in infected Calomys callosus. Research in Veterinary Science 2008; 85: 515–21
Cutrullis R.A. Poklépovich TJ, Postan M, Freilij HL, Petray PB. Immunomodulatory and antifibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosma cruzi infection International Immunopharmacology, 2011; 11: 1024 –1031
DOI: http://dx.doi.org/10.18103/imr.v3i7.523
Refbacks
- There are currently no refbacks.